Skip to main content
2022 Guide to Patient Support Services

Takeda Oncology

2022 Oncology Guide to Patient Support Services

Takeda Oncology Here2Assist Services

Takeda Oncology offers the Here2Assist support program to help patients who are prescribed a Takeda Oncology treatment (Table).

Takeda Oncology Here2Assist

Here2Assist case managers provide personalized support to your patients with services such as the RapidStart Program, the Takeda Oncology Co-Pay Assistance Program, the Takeda Oncology Patient Assistance Program, and the Velcade Reimbursement Assistance Program.

RapidStart Program

If your patient experiences a delay due to insurance coverage determination of at least 5 business days, they may be eligible to receive a 1-month supply of their prescribed Takeda Oncology medication at no cost. Click here to learn more.

Takeda Oncology Co-Pay Assistance Program

Eligible patients who are commercially insured may pay as little as $0 per prescription with an annual cap of $25,000 for their Takeda Oncology medication. Patients may be eligible if they:

  • Have commercial insurance coverage
  • Are at least 18 years of age
  • Do not participate in any federal, state, or other government health insurance program, such as Medicare, Medicaid, TRICARE, Veterans Affairs, or Department of Defense.

To enroll your patient, visit

Takeda Oncology Patient Assistance Program

If your patient is uninsured or underinsured, they may be eligible to receive a monthly supply of Alunbrig, Exkivity, Iclusig, or Ninlaro at no cost. Patients must meet certain financial and insurance coverage criteria to be eligible. Patient Assistance Program Applications are available online.

Velcade Reimbursement Assistance Program

The Velcade Reimbursement Assistance Program includes the Velcade Patient Assistance Program. Under these programs, commercially insured patients can apply for financial assistance, and eligible uninsured or underinsured patients may be able to receive a monthly supply of Velcade at no cost to them. To learn more or to enroll your patient, please visit

Click here to learn more or to enroll your patient in the Takeda Oncology Here2Assist patient support program, or call 844-817-6468.

TABLE Takeda Oncology Drugs

Patient support programs

Alunbrig (brigatinib) tablets
First-line treatment of patients with metastatic non–small-cell lung cancer and ALK mutation, as detected by an FDA-approved test
Patient support programs

Exkivity (mobocertinib) capsules
Treatment of adults with locally advanced or metastatic non–small-cell lung cancer with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
Patient support programs

Iclusig (ponatinib) tablets
Chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia; chronic myeloid leukemia with T315I mutation; Ph+ acute lymphoblastic leukemia with T315I mutation
Patient support programs

Ninlaro (ixazomib)
Treatment of multiple myeloma, in combination with lenalidomide and dexamethasone
Patient support programs

Velcade (bortezomib)
Treatment of multiple myeloma; mantle-cell lymphoma
Patient support programs

Ph+ indicates Philadelphia chromosome–positive.

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"